Medical device company BioVentrix (BVXX.US), which specializes in minimally invasive treatments for heart failure, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday. The company aims to raise up to $17 million through an initial public offering (IPO). BioVentrix focuses on the development and commercialization of medical devices for treating heart failure with reduced ejection fraction (HFrEF). Its core product, the Revivent System, is designed to restore left ventricular function in HFrEF patients with anterior wall scarring resulting from a prior myocardial infarction. The system utilizes titanium anchors connected by a PEEK tether. Via a minimally invasive mini-thoracotomy procedure, it folds the scarred, non-functioning myocardial tissue to reduce left ventricular volume. The surgery is performed on a beating heart and is intended to offer a less invasive alternative to traditional open-heart procedures, such as ventricular assist device implantation or heart transplantation. BioVentrix had previously generated revenue from the sale of its Revivent TC® Transcatheter Ventricular Enhancement System, which was discontinued in 2023 to conserve capital. Founded in 2003 and headquartered in Mansfield, Massachusetts, the company plans to list on the Nasdaq under the ticker symbol BVXX. BioVentrix had confidentially submitted its draft registration statement on August 5, 2025. The Benchmark Company is acting as the sole book-running manager for the proposed offering. Pricing terms for the IPO have not yet been disclosed.